NBIX Neurocrine Biosciences, Inc.

$156.22▼ -0.22% Healthcare Other
After hours $156.22▲ +0.00% Sep 11, 7:30 PM ET
Volume 865.6K Avg Volume (10D) 965.7K
Key Metrics & Fundamentals
Market Cap
$15.88B
P/E Ratio
22.8
Div Yield
–%
52W Range
122.14 - 186.12
% vs 50 MA
-5.15%
% vs 200 MA
5.94%
RSI-14
46.5
MACD Histogram
+0.7000
Beta (1Y vs SPY)
0.64
Free Cash Flow
$128.60M
Gross Rev
$959.00M
Gross Profit
$935.80M
EBITDA
$177.80M
COGS
$23.20M
Operating Exp
$782.80M
Operating Income
$153.00M
EBIT
$153.00M
Pretax Income
$162.20M
Net Income
$144.40M
EPS (Diluted)
1.39
Price & Volume History
Loading chart…
Recent News
Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says
MT Newswires · Sep 8, 2026 3:50 PM
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
PR Newswire · Sep 2, 2026 8:01 PM
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
Zacks · Aug 31, 2026 4:33 PM
Neurocrine Biosciences (NBIX) Wins FDA Trial Nod, Is It Still Below Fair Value?
Simply Wall St. · Aug 28, 2026 2:18 AM
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative?
Simply Wall St. · Aug 27, 2026 4:25 PM
Neurocrine Biosciences (NBIX) Stock Looks Fairly Priced As 64% Gain Holds
Simply Wall St. · Aug 27, 2026 12:14 PM
Neurocrine Biosciences (NBIX) Cleared For Phase 2 Alzheimer’s Cognition Study
Simply Wall St. · Aug 27, 2026 9:07 AM
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
GlobeNewswire · Aug 26, 2026 7:33 AM
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Zacks · Aug 25, 2026 5:26 PM
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Zacks · Aug 20, 2026 3:18 PM
Financial Overview - Income Statement Quarterly

See NBIX's money flow as a full page

Social Sentiment
Avg +0.60 · 2 posts
DDDiscussionTradeBiotech with strong growth and profitability : NBIX
r/wallstreetbets · Jan 28, 2025
The author expresses bullish sentiment and shares holdings, indicating a positive outlook.
positive +0.60
Biotech with strong growth and profitability : NBIX
r/stocks · Jan 28, 2025
The post highlights positive developments like drug approvals and partnerships, suggesting a bullish outlook on the stock.
positive +0.60
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙